An experimental therapy demonstrated promising efficacy when evaluated in a small cohort of patients with advanced head and neck squamous cell carcinoma, according to results of an open-label dose escalation study.

A majority of patients treated with AZD1775 (AstraZeneca) — a highly selective small molecule inhibitor of the WEE1 kinase — underwent successful surgery.